Dr Sophie Allauzen

Sophie is a Senior Programme Officer (SPO) for Global Health Diagnostics at the Bill and Melinda Gates Foundation.  Her main interest is to explore innovate diagnostic approaches to solving health problems in the context of the developing world. She is currently overseeing the malaria diagnostic programme working with various selected partner institutions to develop novel diagnostic tools to support the foundation's overall malaria strategy for malaria eradication termed “Accelerate to Zero”. 

Sophie’s background includes 15 years of Diagnostics international experience in R&D, business development, and portfolio management. She comes from Novartis Diagnostics where she was the Head of Blood Testing, overseeing the NAT/Immunohematology product portfolio from development to launch and directing the research group, focused on multiple alliances to expand the application of proprietary technologies. Prior to that, she worked at Bio-Rad where she managed the R&D department for the development of bead multiarray immunoassays and implemented a new research center in Shanghai dedicated to novel methods for developing/producing Monoclonal Antibodies. Before moving to the USA., she spent 5 years with Sanofi Diagnostics Pasteur R&D working on the development of various tests for infectious diseases. Sophie holds a PhD in Biochemistry/Immunology from the University of Montpellier, France, directed toward Auto-Immune disease mechanisms, and held a Postdoc fellow position in Allergy at University of Minnesota.

Sophie supports the work of the Diagnostics Modelling Consortium malaria project.